Background: Disseminated pediatric low-grade gliomas and glioneuronal tumors (dpLGG/GNTs) are associated with a poorer prognosis than nondisseminated pLGG/GNTs. To date there is no comprehensive report characterizing the genome profile of dpLGG/GNTs and their relative survival. This systematic review aims to identify the pattern of genetic alterations and long-term outcomes described for dpLGG/GNT.

Methods: A systematic review of the literature was performed to identify relevant articles. A quality and risk of bias assessment of articles was done using the GRADE framework and ROBINS-I tool, respectively.

Results: Fifty studies published from 1994 to 2020 were included in this review with 366 cases reported. There was sporadic reporting of genetic alterations. The most common molecular alterations observed among subjects were 1p deletion (75%) and fusion (55%). BRAF p.V600E mutation was found in 7% of subjects. A higher proportion of subjects demonstrated primary dissemination compared to secondary dissemination (65% vs 25%). First-line chemotherapy consisted of an alkylation-based regimen and vinca alkaloids. Surgical intervention ranged from biopsy alone (59%) to surgical resection (41%) and CSF diversion (28%). Overall, 73% of cases were alive at last follow-up. Survival did not vary by tumor type or timing of dissemination. All studies reviewed either ranked low or moderate for both quality and risk of bias assessments.

Conclusions: Chromosome 1p deletion and fusion were the most common alterations identified in dpLGG/GNT cases reviewed. The relative molecular heterogeneity between DLGG and DLGNT, however, deserves further exploration and ultimately correlation with their biologic behavior to better understand the pathogenesis of dpLGG/GNT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639355PMC
http://dx.doi.org/10.1093/noajnl/vdac122DOI Listing

Publication Analysis

Top Keywords

systematic review
12
disseminated pediatric
8
pediatric low-grade
8
glioneuronal tumors
8
genetic alterations
8
quality risk
8
risk bias
8
clinical molecular
4
molecular features
4
features disseminated
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

STEM Neurology & Neuropsychological0 Research Group Egypt (SNRGE), Port Said, Port Said, Egypt.

Background: Donepezil, an acetylcholinesterase inhibitor (AChEI), is an FDA-approved drug to treat these neurodegenerative diseases, e.g., Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI).

View Article and Find Full Text PDF

Background: Gamma desynchronization is an early pathophysiological event in Alzheimer's disease with a disturbance in oscillation in the gamma frequency range 30-80 Hz. This disruption was found to be directly related to the disease progression and severity. Thus, the use of transcranial alternating current stimulation (tACS) possessed greater interest.

View Article and Find Full Text PDF

Intubation of patients requiring cervical spine immobilization can be challenging. Recently, the use of C-MAC video laryngoscopes (VL) has increased in popularity over direct laryngoscopy (DL). We aimed to conduct a systematic review and meta-analysis to evaluate the efficacy of C-MAC VL as compared with DL for intubation in C-spine immobilized patients.

View Article and Find Full Text PDF

Background: Solanezumab, a promising treatment for Alzheimer's disease, has captured the attention of the medical community. This monoclonal antibody is designed to target and clear beta-amyloid plaques, a hallmark feature of Alzheimer's, from the brain. While initial clinical trials showed mixed results, ongoing research is exploring its potential to slow cognitive decline and improve the lives of those affected by this devastating neurodegenerative condition.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common form of dementia. Although AD is characterized by the accumulation of amyloid beta (Aβ) plaques and neurofibrillary tangles (NFTs), it's estimated that nearly half of AD cases might be attributed to modifiable risk factors and lifestyle-based interventions may offer promising preventative strategies to delay disease onset and progression. Polyphenolic derivatives easily found in foods like luteolin and curcumin have shown beneficial effects to counteract cognitive decline.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!